RecruitingPHASE1, PHASE2NCT04065399
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Studying Acute myeloid leukemia with 11q23 abnormalities
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Syndax Pharmaceuticals
- Principal Investigator
- Angela R Smith, M.D.Syndax Pharmaceuticals
- Intervention
- revumenib(drug)
- Enrollment
- 447 enrolled
- Eligibility
- All sexes
- Timeline
- 2019 – 2027
Study locations (30)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University Of California Care Medical Group - Norris Comprehensive Cancer Center And Hospital, Los Angeles, California, United States
- Stanford Cancer Institute, Palo Alto, California, United States
- University of Colorado, Aurora, Colorado, United States
- Florida Cancer Specialists and Research Institute, Sarasota, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Emory Winship Cancer Institute, Atlanta, Georgia, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- The University of Chicago Medical Center, Chicago, Illinois, United States
- University of Iowa Hospital, Iowa City, Iowa, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University in St. Louis School of Medicine, St Louis, Missouri, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Montefiore Medical Center, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04065399 on ClinicalTrials.govOther trials for Acute myeloid leukemia with 11q23 abnormalities
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06710418Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/LeukemiaUniversity of Washington
- RECRUITINGPHASE3NCT07007312Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLKura Oncology, Inc.
- RECRUITINGPHASE1, PHASE2NCT06928662Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of RelapseFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT07106749CD180 CART for Relapsed or Refractory CD180 Positive Hematologic MalignanciesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT06448013A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06245746UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid LeukemiaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNCT06452732Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AMLPeking University People's Hospital
- RECRUITINGNCT06458257The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid LeukemiaRuijin Hospital
See all trials for Acute myeloid leukemia with 11q23 abnormalities →